How I treat chronic graft-versus-host disease.

Allogeneic stem cell transplantation (SCT) is now a commonplace procedure. Clinicians who care for patients with hematologic malignancies and aplastic anemia are almost certain to follow up patients after SCT. This review is intended to help clinicians observe patients for probably the most important late complication of SCT, chronic graft-versus-host disease (GVHD). It reviews the pathophysiology, risk factors, clinical manifestations, evaluation, treatment, and supportive care of chronic GVHD.

[1]  S. Piantadosi,et al.  Development of a prognostic model for grading chronic graft-versus-host disease. , 2001, Blood.

[2]  E. Farmer,et al.  Etretinate therapy for refractory sclerodermatous chronic graft-versus-host disease. , 1999, Blood.

[3]  H. Hönigsmann,et al.  Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. , 1998, Blood.

[4]  J. Ferrara,et al.  Graft-versus-host disease: the influence of type 1 and type 2 T cell cytokines. , 1998, Transfusion medicine reviews.

[5]  B. Bierer,et al.  Treatment of chronic graft-versus-host disease with clofazimine. , 1997, Blood.

[6]  E. Farmer,et al.  Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA). , 1996, Bone marrow transplantation.

[7]  A. Mazumder,et al.  The effect of hydroxychloroquine on alloreactivity and its potential use for graft-versus-host disease. , 1996, Bone marrow transplantation.

[8]  W. Krenger,et al.  Graft-versus-host disease and the Th1/Th2 paradigm , 1996, Immunologic research.

[9]  Charles E. Kahn,et al.  graft-vs.-host disease , 1995 .

[10]  C. Sidman,et al.  Differential cytokine expression in acute and chronic murine graft‐versus‐host‐disease , 1993, European journal of immunology.

[11]  A. Hess,et al.  Cyclosporine-induced syngeneic graft-versus-host disease: recognition of self MHC class II antigens in vivo. , 1993, Transplantation proceedings.

[12]  P. De Baetselier,et al.  Preferential activation of Th2 cells in chronic graft-versus-host reaction. , 1993, Journal of immunology.

[13]  C. Shanley,et al.  Total lymphoid irradiation for treatment of drug resistant chronic GVHD. , 1993, Bone marrow transplantation.

[14]  D. Jabs,et al.  Thalidomide for the treatment of chronic graft-versus-host disease. , 1992, The New England journal of medicine.

[15]  T. Starzl,et al.  FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. , 1991, Transplantation proceedings.

[16]  K. Sullivan,et al.  Chronic graft-versus-host disease and other late complications of bone marrow transplantation. , 1991, Seminars in hematology.

[17]  H. Deeg,et al.  Transfusions shortly before HLA-matched marrow transplantation for leukemia are associated with a decrease in chronic graft-versus-host disease. , 1991, Bone marrow transplantation.

[18]  T. Lamparelli,et al.  Cyclosporin A and chronic graft versus host disease. , 1990, Bone marrow transplantation.

[19]  M. Pepe,et al.  Cytomegalovirus infection after marrow transplantation for aplastic anemia. , 1990, Bone marrow transplantation.

[20]  C. Perreault,et al.  Minor histocompatibility antigens. , 1990, Blood.

[21]  K. Sullivan,et al.  Value of day 100 screening studies for predicting the development of chronic graft-versus-host disease after allogeneic bone marrow transplantation. , 1990, Blood.

[22]  A. Rimm,et al.  Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. , 1990, Blood.

[23]  O. Ringdén,et al.  A European multicenter study of chronic graft-versus-host disease. The role of cytomegalovirus serology in recipients and donors--acute graft-versus-host disease, and splenectomy. , 1990, Transplantation.

[24]  P. Ljungman,et al.  LONG‐TERM CYCLOSPORIN THERAPY MAY DECREASE THE RISK OF CHRONIC GRAFT‐VERSUS‐HOST DISEASE , 1990, British journal of haematology.

[25]  J. Pierga,et al.  Low-dose (one gray) total-lymphoid irradiation for extensive, drug-resistant chronic graft-versus-host disease. , 1990, Transplantation.

[26]  S. Piantadosi,et al.  Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. , 1989, Blood.

[27]  A. Rimm,et al.  Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry. , 1989, Bone marrow transplantation.

[28]  Jean E. Sanders,et al.  Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. , 1988, Blood.

[29]  H. Deeg,et al.  Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. , 1988, Blood.

[30]  E. Elonen,et al.  Low incidence of severe acute and chronic graft-versus-host disease as a result of prolonged cyclosporine prophylaxis and early aggressive treatment with corticosteroids. , 1988, Transplantation proceedings.

[31]  K. Atkinson,et al.  PUVA therapy for drug-resistant graft-versus-host disease. , 1986, Bone marrow transplantation.

[32]  K. Sullivan,et al.  Second marrow infusion for poor graft function after allogeneic marrow transplantation. , 1986, Bone marrow transplantation.

[33]  E. Farmer,et al.  Methoxsalen and ultraviolet A radiation in treatment of chronic cutaneous graft-versus-host reaction. , 1985, Journal of the American Academy of Dermatology.

[34]  H. Deeg,et al.  CYCLOSPORIN A AND METHOTREXATE IN CANINE MARROW TRANSPLANTATION: ENGRAFTMENT, GRAFT‐VERSUS-HOST DISEASE, AND INDUCTION OF TOLERANCE , 1982, Transplantation.

[35]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.